SightGlass Vision has shared positive outcomes of multiple studies evaluating its Diffusion Optics Technology spectacle lenses, designed to slow myopia progression in children.

Presenting at the 2023 ARVO Annual Meeting in New Orleans, SightGlass said results of 42-month data from the CYPRESS study extension reinforced the safety and efficacy of Diffusion Optics Technology lenses in children aged 6-10. The latest investigation re-enrolled 98 participants from the original three-year, double-masked, randomised, multi-site clinical trial to generate six additional months of data. Outcomes demonstrated statistically significant improvements in axial length (AL) and cycloplegic spherical equivalent refraction (cSER) between the test and control groups, according to the company.

Researchers calculated age-independent myopia AL growth to evaluate Diffusion Optics Technology lens efficacy. Physiological AL growth was determined based on age-matched emmetropic eye-growth data from the Orinda Longitudinal Study of Myopia, then compared to AL growth observed in the original three-year CYPRESS study. Children in the test lens group showed 0.23mm (73%, p=0.003) less pathological AL change than those in the control group (test: 0.08 ± 0.06mm; control: 0.31 ± 0.05mm).

In addition to the featured CYPRESS presentations, SightGlass Vision and its research partners displayed several posters at ARVO, including a study from the Centre for Ocular Research & Education (CORE) showing that Diffusion Optics Technology spectacle lenses have no significant effect on accommodative lag after short-term wear.

Spectacle lenses with SightGlass Vision Diffusion Optics Technology use thousands of micro-dots to softly scatter light, reducing the contrast on the retina. Over the last 18 months, the technology made its commercial debut in China, the Netherlands and Israel, as well as through preliminary market trials elsewhere.